Immutep Ltd ADR - Asset Resilience Ratio
Immutep Ltd ADR (IMMP) has an Asset Resilience Ratio of 17.92% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Immutep Ltd ADR (IMMP) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Immutep Ltd ADR's Asset Resilience Ratio has changed over time. See IMMP equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Immutep Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Immutep Ltd ADR stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $26.38 Million | 17.92% |
| Total Liquid Assets | $26.38 Million | 17.92% |
Asset Resilience Insights
- Good Liquidity Position: Immutep Ltd ADR maintains a healthy 17.92% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Immutep Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Immutep Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Immutep Ltd ADR (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Immutep Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 39.68% | $62.28 Million | $156.98 Million | +29.71pp |
| 2024-06-30 | 9.96% | $20.09 Million | $201.58 Million | -- |
| 2023-06-30 | 0.00% | $0.00 | $147.45 Million | -- |
| 2019-06-30 | 0.00% | $0.00 | $40.54 Million | -- |
| 2018-06-30 | 0.00% | $0.00 | $47.00 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $34.96 Million | -- |
| 2016-06-30 | 0.00% | $0.00 | $42.55 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $30.98 Million | -- |
| 2014-06-30 | 35.46% | $9.00 Million | $25.38 Million | +11.08pp |
| 2013-06-30 | 24.38% | $8.00 Million | $32.81 Million | -26.19pp |
| 2012-06-30 | 50.57% | $21.05 Million | $41.61 Million | +33.23pp |
| 2011-06-30 | 17.35% | $10.00 Million | $57.64 Million | -- |
About Immutep Ltd ADR
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more